SE

Anders Forslund

This inventor holds 0 USPTO granted patents, plus 1 CIPO patent.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anders Forslund. Retrieved from https://idiyas.com/inventor/anders-forslund-arstcz51

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

 

Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: Anders Forslund: A Contributor to Innovative Pharma Solutions

Introduction

Anders Forslund is a notable professional based in Sweden who currently works at Empros Pharma AB. While he has not registered any patents as of now, his contributions to the pharmaceutical industry are significant through his work and collaborations.

Latest Patents

Anders Forslund currently holds no patents to his name. This may reflect his role in the industry as a contributor rather than a primary inventor. Nevertheless, his expertise is valuable in advancing pharmaceutical innovations.

Career Highlights

Employed at Empros Pharma AB, Anders has focused on developing and improving pharmaceutical solutions. His career has been marked by a commitment to enhancing drug delivery systems and promoting clinical advancements.

Collaborations

Throughout his career, Anders has worked closely with talented colleagues such as Goran Alderborn and Ulf Holmback. These collaborations have likely fostered creativity and innovation within their projects at Empros Pharma AB.

Conclusion

Though Anders Forslund has not filed any patents, his work at Empros Pharma AB and collaborations with skilled professionals highlight his significant role in the field of pharmaceuticals. As technology and research continue to evolve, his contributions may pave the way for future innovations in the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…